Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib with Chemotherapy in Pediatric FLT3-Mutated AML
NCT03324243Phase 2Withdrawn
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of crenolanib in acute myeloid leukemia (AML), sponsored by AROG Pharmaceuticals, Inc.. Planned start Jan 2018; status: withdrawn.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03324243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03324243.